We use ERT’s High Precision QT methodology to do Expert Precision QT (EPQT)
- 10-fold more data points than current semi-automated methods
- Higher quality QRST complexes; very low data variability
- Greater precision, hence more cost-effective drug development
- Fewer false positive and inconclusive results
- Potential waiver of the later stage, mandatory and costly ($2–5 million) TQT trials
- Informed decision-making process across the entire drug development portfolio
- EPQT is supported by a global consortium of regulators and pharma companies
- Recommended analysis includes Method Bias Sensitivity (MBS)
- MBS analysis gives regulators certainty that the ECG core lab hasn’t introduced bias into the test results